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Abstract 
Acquired factor XIII (FXIII) deficiency is a rare and life-threatening condition which is 
often misdiagnosed or missed completely.  A 72 year old woman presented with 
symptoms of major unprovoked bleeding but routine coagulation screening tests and 
platelet count were normal. Low FXIIIa activity levels and abnormal urea clot stability 
led to diagnosis of acquired FXIII deficiency. A modified Bethesda inhibitor titre of 1.6 
BU/ml indicated the presence of a FXIII inhibitor. Bleeding responded to a single 
dose of FXIII concentrate and immunosuppression with prednisolone induced 
remission.  A subsequent relapse was treated with combined prednisolone and 
Rituximab resulting in a prolonged, ongoing remission. Here we analyse the 
mechanisms underlying this idiopathic case of acquired FXIII deficiency.   
Prospective analysis of patient plasma revealed minimal FXIIIa activity and antigen 
in presentation and relapse samples.  Thrombi formed from these samples lysed 
rapidly and showed an absence of cross-linked 2AP. Western blotting revealed the 
presence of FXIII-B, indicating only FXIII-A and FXIII-A2B2 were affected.  FXIII 
activity and antigen levels normalised on remission. Our data suggest the presence 
of inhibitor induced clearance of FXIII from plasma.  As a consequence reduced 
thrombus stability was evident due to defective 2AP cross-linking, thereby 
explaining symptoms of excessive bleeding. 
  
Introduction 
Plasma factor XIII (FXIII) circulates as a heterodimer, A2B2, and is activated by 
thrombin and calcium to become a transglutaminase (TG) enzyme (Lorand and 
Konishi 1964, Schwartz, et al 1973). FXIII functions in haemostasis by cross-linking 
the  - and - chains (Gladner and Nossal 1983) of fibrin in order to increase the 
mechanical stability of clots and confers fibrinolytic resistance by cross-linking 
fibrinolysis inhibitors, such as 2-antiplasmin (2AP), to fibrin (Sakata and Aoki 1980). 
The importance of FXIII in maintaining haemostasis is made evident in clinical cases 
of its severe deficiency. Congenital FXIII deficiency is a rare autosomal recessive 
disorder  characterised by a severe haemorrhagic diathesis, including unprovoked 
umbilical stump and intracranial bleeding (Aziz and Siddigui 1972, Losowsky, et al 
1965), abnormal wound healing (Aziz and Siddigui 1972, Fisher, et al 1966) and 
spontaneous miscarriage in women (Fisher, et al 1966). Cases of mild and moderate 
deficiency of FXIII resulting from reduced synthesis or increased consumption are 
described in association with several medical conditions including Crohn’s disease, 
ulcerative colitis, liver disease, sepsis and disseminated intravascular coagulation. In 
general, however, in these cases the patients have a moderate reduction in FXIII-A 
subunit levels and rarely present with unprovoked bleeding (Kohler, et al 2011). On 
the other hand, severe acquired FXIII deficiency is an exceptionally rare disorder with 
less than 100 cases described (Souri, et al 2015). The most common conditions 
associated with antibody mediated acquired FXIII deficiency are connective tissue 
disorders and malignancy but around half of the cases reported have no clear 
associated disorder (Boggio and Green 2001). Treatment with FXIII concentrate to 
arrest bleeding and immunosuppressive therapy to eliminate autoantibodies is 
required.  
Unlike most single coagulation factor deficiencies, FXIII deficiency cannot be detected 
using routine clot based coagulation tests.   This often leads to delayed or 
misdiagnosis of this condition which delays necessary treatment. Here we describe 
the clinical and laboratory characteristics of a patient that presented with idiopathic 
acquired FXIII deficiency.  We have sequentially analysed the effects of the 
autoantibody on FXIII activity and in fibrinolytic assays.  
  
Methods 
Patient plasma samples 
Samples of patient plasma from the time of initial presentation, relapse and remission 
were stored at -70oC until the time of analysis. 
 
Collection of blood and preparation of plasma  
Pooled normal plasma (PNP) that was essentially free of platelets was prepared from 
20 normal donors as previously described (Booth, et al 1988).   
 
FXIII activity assay 
FXIII activity was quantified using an in-house activity assay as previously described 
(Mitchell, et al 2014). 
 
Chandler model thrombus lysis 
Chandler model thrombus lysis was performed as previously described (Mutch, et al 
2010). Patient plasma samples, PNP or commercial FXIII-depleted plasma (Affinity 
Biologicals, Ancaster, ON, Canada) containing fluorescein isothiocyanate (FITC)-
labelled fibrinogen (43.5 g/ml), with a FITC/fibrinogen ratio of approximately 6:1, were 
recalcified (10.9 mM CaCl2). The loops were rotated for 90 min at 30 r.p.m. Formed 
thrombi were washed in 0.9% (w/v) NaCl and bathed at 37oC in 10 mM Tris, 0.01% 
Tween 20, pH 7.4 containing 1 g/ml single-chain tissue-type plasminogen activator 
(tPA; Genetech, San Francisco, CA, USA). Samples were taken at 30 min intervals 
for 4 h. Fluorescence was read, excitation 485 nm and emission 528 nm, on a Biotek 
Instruments Fluorometer. After 4 h of lysis, thrombi were dissolved in 8 M urea, 0.2 M 
Tris (pH 8), 40 mM dithiothreitol and 4 % sodium dodecyl sulphate (SDS) at 37°C for 
12 h for Western blotting.  
 
Western blotting 
Patient plasma samples or dissolved thrombi were run on 4–12% polyacrylamide bis–
Tris NuPAGE gels with MOPS running buffer (Life Sciences, Paisley, UK) under 
reducing conditions. Fibrogammin P® (20 g/ml; CSL Behring, Sussex, UK) was 
included as a positive control for the FXIII-B2 subunit. Proteins were transferred to 
nitrocellulose and immunoblotted with a polyclonal antibody for FXIII-B (200 ng/ml; sc-
18015 Santa Cruz Biotechnology, Santa Cruz, CA, USA) or a polyclonal antibody to 
2AP (2.5 g/ml; SA2AP-IG, Affinity Biologicals). Appropriate horseradish-peroxidase 
(HRP)-conjugated secondary antibodies, were applied and proteins were detected 
using ECL (Thermo Fisher-Scientific, Leicestershire, UK) with a UVP Biospectrum 810 
system and analysed with UVP visionWorks LS Image Acquisition and Analysis 
software. 
FXIII ELISA 
FXIII-A antigen was measured using a ZYMUTEST FXIII-A ELISA kit (Hyphen 
Biomed, # RK034A; Quadratech Diagnostics LTD, Surrey, UK). Patient plasma 
samples, normal pooled plasma (PNP) or FXIII depleted plasma were diluted 1:50 and 
added to plates pre-coated with a sheep polyclonal antibody specific for human FXIII-
A and incubated for 1 h in the presence of Anti-(h)-FXIII-HRP immunoconjugate. Wells 
were then washed 5 times and colour was developed using a 3,3',5,5' – 
Tetramethylbenzidine containing hydrogen peroxide and stopped after 5 min with 0.45 
M sulphuric acid. The absorbance was measured at 405 nm using a Labsystems iEMS 
plate reader. 
 
Clinical Case 
A 72 year old woman presented with extensive, unprovoked soft tissue bleeding on 
the limbs and trunk (Figure 1A.), and a large splenic haematoma was confirmed by 
CT scan. There was no previous personal or family history of pathological bleeding. 
The patient had a history of uncomplicated, significant previous haemostatic 
challenges including dental surgery and parturition. She was not taking any 
medication. Routine laboratory investigations showed anaemia with an otherwise 
normal full blood count. PT, aPTT and fibrinogen levels by Clauss assay were normal. 
Further investigation revealed abnormal urea clot stability tests which did not fully 
correct upon addition of normal plasma. FXIII activity, as measured by the Dade 
Behring Berichrom® FXIII activity kit, was significantly reduced at 0.09 U/ml (Normal 
Range: 0.59-1.63; Figure 1B.). A modified Bethesda inhibitor titre of 1.6 BU/ml was 
measured, indicating the presence of a FXIII inhibitor.  
Repeated clinical examination, chest X-rays (smoker), whole body CT scan and 
autoantibody studies have continued to date (3 years from presentation) and  show no 
evidence of underlying malignancy or connective tissue disease. The patient was 
treated with a single dose of FXlll concentrate (Fibrogammin P®) and was commenced 
on immunosuppression with prednisolone 1 mg/kg. Following treatment there were no 
further bleeding episodes and serial scans showed progressive improvement in the 
splenic haematoma.  High dose steroid treatment was continued until normalisation of 
the urea clot stability tests, which coincided with normalisation of the quantitative FXIII 
assay. 
Seven weeks after stopping steroids, there was laboratory evidence of relapse with 
abnormal urea clot stability test but  no associated clinical symptoms of bleeding.. This 
was confirmed by repeat measurements using the Dade Behring Berichrom® FXIII 
activity assay. The patient was recommenced on steroids and was given rituximab 
375 mg/ m2 weekly for four weeks. She showed a positive response to treatment as 
evidenced by normalisation of the urea clot stability test and FXIII assay. The patient 
has now been off all immunosuppressive treatment for around 2 years with no 
evidence of an emerging underlying disorder.  
 
Characterisation of FXIII activity and expression 
Samples of the patient’s blood were taken and stored throughout the treatment time 
from initial presentation to remission and plasma samples were subsequently 
analysed in order to characterize the mechanisms underlying the clinical progression.   
FXIIIa activity and antigen are depleted in patient plasma  
Patient plasma was assessed for both FXIII activity and FXIII antigen levels in order 
to determine whether deficiency resulted from the absence of FXIII or the presence of 
non-functional protein. 
 
FXIIIa activity was quantified in patient plasma using an in-house activity assay 
(Mitchell, et al 2014) and FXIII-A antigen was measured using a commercial ELISA 
(ZYMUTEST). FXIIIa activity levels and the FXIII-A antigen in the initial presentation 
patient plasma sample were below the limits of detection in both assays. In the relapse 
samples low levels of activity (0.1 IU/ml) and antigen (39%) were detected (Figure 2A-
B.). The values were substantially lower than those obtained with a normal plasma 
control (0.43 IU/ml and 111% respectively).  
 
Western blotting using an antibody specific to the FXIII-B subunit in patient plasma 
samples revealed FXIII-B antigen in the initial presentation, relapse and remission 
samples. This suggests that only FXIII-A and FXIII-A2B2 have been cleared from 
plasma by the inhibitor, leaving circulating levels of FXIII-B. (Figure 2C.) 
 
The ability of the inhibitor in the patient’s plasma to neutralize the activity of purified 
FXIII (Fibrogammin P®) was further examined using an in-house activity assay. 
Purified FXIII (final concentration - 0.5 U/ml) was mixed with increasing percentages 
of patient plasma from initial presentation. Interestingly, there were no differences in 
FXIII activity levels from 20% to 80% patient plasma (Fig 5.2D) These findings contrast 
with those from the modified Bethesda assay performed on the initial and relapse 
samples and point towards a time and temperature dependent inhibition of FXIII-A. 
Patient model thrombi are susceptible to fibrinolysis due to a lack of cross-linked 2AP 
Model thrombi formed from patient plasma taken at the time of initial presentation 
(194.6 FU/min-1) and relapse (183.5 FU/min-1) lysed rapidly relative to normal plasma 
(17.7 FU/min-1), with lysis rates similar to that of commercial FXIII-depleted plasma 
(186.6 FU/min-1) (Figure 3A.). FXIII exerts antifibrinolytic activity by cross-linking 2AP 
to fibrin, thereby stabilizing clots against fibrinolytic degradation. Western blotting of 
dissolved patient thrombi revealed free 2AP, but a clear absence of cross-linked 2AP 
in thrombi formed from initial presentation and relapse patient plasma samples 
compared to the normal plasma control samples (Figure 3B.).  
 
 
Discussion 
Here we report a case of acquired FXIII deficiency due to a plasma based anti-FXIII-A 
inhibitor which demonstrates time and temperature dependant characteristics (Kohler, 
et al 2011). Idiopathic acquired FXIII deficiency is rare, can be difficult to treat and is 
associated with significant mortality and morbidity. It can be caused by the 
development of an inhibitor to FXIII or by disruption to the production and activity of 
the FXIII molecule.  
The clinical features observed in this case are characteristic of acquired FXIII. The 
response to treatment with FXIII concentrate (Fibrogammin P®) to control bleeding 
was brisk, although this is not always the case (Gregory and Cooper 2006, Hayashi, 
et al 2012, Ichinose, et al 2015)  The early response of the inhibitor to prednisolone 
therapy was however short-lived and the response to the combination of prednisolone 
combined with rituximab has been much more persistent.  
In this case, FXIII antigen and activity levels in the patient’s plasma obtained at initial 
presentation were below the lower limit of detection of both assays, suggesting 
complete clearance from the patient’s circulation. Thrombi formed from initial 
presentation samples lysed at a similarly rapid rate to commercial FXIII-depleted 
plasma and contained no cross-linked 2AP. At the time the laboratory detected 
relapse, the activity and antigenic levels were 0.1IU/mL and 39% respectively, there 
was no evidence of renewed bleeding in the patient, however thrombi formed from 
the relapse samples lysed rapidly and revealed an absence of cross-linked 2AP, 
similar to the initial presentation samples. This suggests that the low activity levels of 
FXIII (0.1 IU/mL) were not sufficient to facilitate significant 2AP cross-linking. This 
observation is in line with our previous report which demonstrated that levels of 50% 
plasma FXIII are necessary to achieve adequate 2AP cross-linking (Fraser, et al 
2011). Fibrin-fibrin cross-links induced by FXIIIa confer mechanical stability to 
thrombi (Mockros, et al 1974, Shen and Lorand 1983) and could partially account for 
the bleeding complications observed in the patient. Thrombi formed in mice in the 
absence of FXIII are smaller in size due to lack of retention of red blood cells 
(Aleman, et al 2014).  This unique mechanism, involving an interaction between red 
blood cells and fibrinogen, could account for some of the clinical features observed 
in the acquired FXIII deficient patient.  
The BCSH guidelines recommend diagnosis of FXIII deficiency using either ammonia 
release or amine incorporation assays for FXIII activity and immunoassays for both A 
and B subunits to detect FXIII antigen. Recommended diagnosis of acquired FXIII 
deficiency is through the use of mixing studies with normal plasma and analysis of 
FXIII activity in platelet lysates, which under these circumstances, should be normal 
(Mumford, et al 2014). The urea clot solubility test is not currently recommended but 
we have shown it can be a useful additional test in the diagnosis and monitoring of 
relapse, particularly in situations in which activity tests are not readily available or 
reliable.  
The Bethesda inhibitor titre of 1.6 BU/ml indicated the presence of a plasma based 
FXIII inhibitor, however, no change was detected in the activity of purified FXIII 
(Fibrogammin P®) when mixed with increasing concentrations of patient plasma from 
the initial presentation (Figure 2D). This in-house activity assay is performed 
immediately post-mixing of the sample. The different set up of these assays, one 
performed immediately at room temperature (in-house FXIIIa activity assay) while the 
other following a 2 h pre-incubation at 37C (Bethesda test) indicate that the acquired 
inhibitor may neutralise FXIII in a time and temperature dependent manner.  Indeed, 
this form of progressive inhibitor is well described for factor VIII which, in contrast to 
fast acting acquired inhibitors to factor IX, requires prolonged incubation with plasma 
to exert inhibitory function.  
FXIII autoantibodies have been reported in a rising number of case studies in recent 
years, particularly in Japan (Ichinose, et al 2015). A recent study investigating 
autoantibody mediated acquired FXIII deficiency describe three types of inhibitor: 
Type Aa, which inhibits FXIII by blocking the assembly of the A and B subunits, and 
also dissociates the A subunit from the B subunit. Type Ab antibodies inhibit the 
action of activated FXIII and type B accelerate the clearance of FXIII-A2B2 from the 
circulation (Ichinose, et al 2015). This patient shows no detectable FXIII-A2 or FXIII-
A2B2 and low levels of the B-subunit present, presumed to be free circulating FXIII-B. 
The presence of FXIII-B in plasma suggests that the inhibitory antibody is targeted 
towards the FXIII-A subunit.  
Unfortunately, further studies on the mechanism of action of this inhibitor were 
prohibited due to a lack of sample. A recent publication (Souri, et al 2015) reports an 
autoantibody with the ability to both block the assembly of FXIII-A2B2 and also ‘steal’ 
FXIII-A that is already in complex with FXIII-B. Patients with this type of antibody had 
reduced FXIII-A antigen and activity, similar to what we have reported. The 
characterised antibodies also blocked activation of FXIII, but interestingly had no 
inhibitory activity towards activated FXIII-A (Souri, et al 2015). Further study would 
have been necessary to examine the inhibitory capacity of the autoantibody we have 
reported towards pre-activated FXIIIa in order to determine whether our data fits with 
the profile of this antibody type. 
In summary, we have reported a case of autoimmune acquired FXIII deficiency that 
was successfully treated with Rituximab therapy. Further analysis of patient plasma 
showed a dramatic reduction in FXIII-A antigen and activity, suggesting the presence 
of a strong inhibitor to FXIII-A. The presence led to defective 2AP cross-linking and 
reduced thrombus stability, manifesting in excessive bleeding in the patient. This 
report, in line with others, describing cases of acquired FXIII inhibitors, highlights the 
requirement for standardised screening and increased awareness of bleeding 
disorders which present with normal platelet counts and coagulation screening tests.  
Such improvements would prevent the failure to detect potentially fatal disorders such 
as FXIII deficiency. 
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Legends 
Figure 1: Clinical presentation and measurements. (A) Photographs taken at the 
time of initial presentation illustrating extensive bruising to limbs and torso and leg 
swelling. (B) Clinical measurements of FXIII activity using a Dade Behring 
Berichrom® FXIII activity kit taken at various time points throughout case 
presentation. 
 
Figure 2: FXIII-A antigen and activity are absent from patient plasma. (A) FXIII 
activity (IU/ml) (A) and FXIII-A antigen (B) was measured in pooled normal plasma, 
FXIII-depleted plasma and patient plasma samples by in-house activity assay and 
ELISA respectively. Antigen values are expressed as % FXIII-A determined by 
calibrated control standard plasma. (C) Pooled normal plasma, FXIII-depleted 
plasma and patient plasma were separated under reducing conditions on NuPAGE 
4-12% gels before transferring to nitrocellulose and probing with a specific antibody 
to the FXIII-B subunit. (D) FXIII activity (IU/ml) was measured in FXIII-depleted 
plasma and the initial presentation (IP) plasma with and without the addition of 0.5 
U/ml purified FXIII (final concentration) by in-house activity assay. 
 
Figure 3: Patient model thrombi are highly susceptible to fibrinolysis. (A) Model 
thrombi were prepared under flow from either FXIII-depleted plasma (Δ); pooled 
normal plasma (▲); initial presentation patient plasma (■) or relapse patient plasma 
(●) with incorporated fluorescently-labelled fibrinogen. Thrombi were lysed in a 
bathing buffer containing 1 g/ml single-chain tissue-type plasminogen activator (t-
PA) and samples were taken every 30 min.  Fluorescence release from thrombi is 
directly proportional to fibrinolysis (B) Model thrombi were dissolved and separated 
under reducing conditions on NuPAGE 4-12% gels before transferring to PVDF and 
probing with a specific antibody to 2AP.  Shown is free 2AP (70 kDa) and cross-
linked 2AP (160 kDa) and above.   
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